References
1. Qaddoumi I, Sultan I, Gajjar A: Outcome and Prognostic Features in
Pediatric Gliomas: a Review of 6212 Cases From the SEER Database. Cancer
115: 5761-5770, 2009.
2. Ochroch EA, Fleisher LA: Evaluating pediatric spinal low-grade
gliomas—a 30-year retrospective analysis. Anesthesiology 105: 643-644,
2019.
3. Fussey JM, Vaidya B, Kim D, Clark J, Ellard S, Smith JA: The role of
molecular genetics in the clinical management of sporadic medullary
thyroid carcinoma: A systematic review. Clin Endocrinol (Oxf) 91:
697-707, 2019.
4. Soiza RL, Donaldson AIC, Myint PK: Molecular targeted therapy of
BRAF-mutant colorectal cancer. Ther Adv Vaccines 9: 259-261, 2018.
5. Chen DS, Mellman I: Elements of cancer immunity and the cancer-immune
set point. Nature 541: 321-330, 2017.
6. Herbst RS, Morgensztern D, Boshoff C: The biology and management of
non-small cell lung cancer. Nature 553: 446-454, 2018.
7. Jørgensen JT: A paradigm shift in biomarker guided oncology drug
development. Ann Transl Med 7: 148, 2019.
8. Rubin JB, Segal RA: Growth, survival and migration: the Trk to
cancer. Cancer Treat Res 115: 1-18, 2003.
9. Laetsch TW, DuBois SG, Mascarenhas L, Turpin B, Federman N, Albert
CM, et al: Larotrectinib for paediatric solid tumours harbouring NTRK
gene fusions: phase 1 results from a multicentre, open-label, phase 1/2
study. Lancet Oncol 19: 705-714, 2018.
10. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et
al: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults
and Children. N Engl J Med 378: 731-739, 2018.
11. Zhao X, Kotch C, Fox E, Surrey LF, Wertheim GB: NTRK Fusions
Identified in Pediatric Tumors: The Frequency, Fusion Partners, and
Clinical Outcome. J Clin Oncol 37: 1234-1242, 2019.
12. Nakagawara A: Trk receptor tyrosine kinases: A bridge between cancer
and neural development. Cancer Lett 169: 107-114, 2001.
13. Amatu A, Sartore-Bianchi A, Siena S: NTRK gene fusions as novel
targets of cancer therapy across multiple tumour types. ESMO Open 1:
e000142, 2016.
14. Torre M, Vasudevaraja V, Serrano J, Delorenzo M, Malinowski S,
Blandin AF, et al: Molecular and clinicopathologic features of gliomas
harboring NTRK fusions. Acta Neuropathol Commun 8: 1-14, 2020.
15. Okamura R, Boichard A, Kato S, Sicklick JK, Bazhenova L, Kurzrock R:
Analysis of NTRK Alterations in Pan-Cancer Adult and Pediatric
Malignancies: Implications for NTRK-Targeted Therapeutics. JCO Precis
Oncol 2: 1-20, 2018.
16. Johnson K, Barragan J, Bashiruddin S, Smith CJ, Tyrrell C, Parsons
MJ, et al: TRK Fusions are Enriched in Cancers with Uncommon Histologies
and the Absence of Canonical Driver Mutations. Physiol Behav 176:
139-148, 2017.
17. Ferguson SD, Zhou S, Huse JT, De Groot JF, Xiu J, Subramaniam DS, et
al: Targetable Gene Fusions Associate With the IDH Wild-Type Astrocytic
Lineage in Adult Gliomas. Mol Cancer Res 18: 512-521, 2020.
18. Gatalica Z, Xiu J, Swensen J, Vranic S: Molecular characterization
of cancers with NTRK gene fusions. Mod Pathol 32: 147-153, 2019.
19. Solomon JP, Linkov I, Rosado A, Mullaney K, Rosen EY, Frosina D, et
al: NTRK fusion detection across multiple assays and 33,997 cases:
diagnostic implications and pitfalls. Mod Pathol 33: 38-46, 2020.
20. Yoshihara K, Wang Q, Torres-garcia W, Zheng S, Vegesna R, Kim H, et
al: The landscape and therapeutic relevance of cancer-associated
transcript fusions. J Clin Oncol 34: 4845-4854, 2016.
21. DuBois SG, Laetsch TW, Federman N, Turpin BK, Albert CM,
Nagasubramanian R, et al: The use of neoadjuvant larotrectinib in the
management of children with locally advanced TRK fusion sarcomas. Cancer
124: 4241-4247, 2018.
22. Deland L, Keane S, Olsson T, Sjögren H, Fagman H, Øra I: Discovery
of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to
targeted treatment with TRK-inhibitor larotrectinib. Cancer Biol Ther
22: 184-195, 2021.
23. Drilon A: TRK inhibitors in TRK fusion-positive cancers. Ann Oncol
30: VIII23-VIII30, 2019.
24. Gambella A, Senetta R, Collemi G, Vallero SG, Monticelli M, Cofano
F, et al: NTRK fusions in central nervous system tumors: A rare, but
worthy target. Int J Mol Sci 21: 1-24, 2020.
25. Adela M, Ales V, Petr B, Katerina V, David S, Lucie S, et al:
Integrated genomic analysis reveals actionable targets in pediatric
spinal cord low-grade gliomas. Acta Neuropathol Commun 10: 1-11, 2022.
26. Range K, MD, Moser YA: TRKing down an old oncogene in a new era of
targeted therapy. Bone 23: 1-7, 2012.
27. Avinash K, Thakar S, Aryan S, Ghosal N, Hegde A: Malignant
Transformation of Pediatric Low-grade Gliomas: Report of Two Cases and
Review of a Rare Pathological Phenomenon. Neurol India 67: 1100-1106,
2019.
28. Drilon A, Laetsch TW, Kummar S, DuBois SG, Lassen UN, Demetri GD, et
al: Efficacy of Larotrectinib in TRK Fusion–Positive Cancers in Adults
and Children. N Engl J Med 378: 731-739, 2018.